Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 6/20 | 0.47 |
| ▸ | HTR1A | P08908 | 4/20 | 0.47 |
| ▸ | VCP | P55072 | 2/20 | 0.42 |
| ▸ | USP2 | O75604 | 6/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.39 |
| ▸ | DHFR | P00374 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11737413 | 0.82 | HTR7 (0.51) | HTR7HTR1AUSP2HSD17B10MAPK1 | |
| SCHEMBL3142372 | 0.79 | LMNA (0.50) | HTR7HTR1AUSP2HSD17B10MAPK1 | |
| SCHEMBL550942 | 0.77 | USP2 (0.55) | USP2MAPK1TSHRALDH1A1SMN1; SMN2 | |
| SCHEMBL14578437 | 0.75 | ADRA2C (0.62) | USP2HSD17B10TSHRALDH1A1SMN1; SMN2 | |
| SCHEMBL8054516 | 0.75 | ADRB1 (0.61) | HTR7USP2TSHRALDH1A1SMN1; SMN2 | |
| SCHEMBL13035710 | 0.73 | BPTF (0.56) | USP2TSHRTP53SMN1; SMN2BRCA1 | |
| SCHEMBL12367085 | 0.73 | DRD2 (0.64) | VCPALDH1A1SMN1; SMN2 | |
| SCHEMBL8276471 | 0.73 | L3MBTL3 (0.47) | VCPUSP2TSHRALDH1A1BRCA1 | |
| SCHEMBL12367104 | 0.73 | PRMT6 (0.46) | HTR7VCPUSP2BRCA1 | |
| SCHEMBL2093308 | 0.72 | ADRB1 (0.63) | HSD17B10MAPK1CYP3A4CYP1A2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050250784-A1 | Inhibitors of histone deacetylase | MIIKANA THERAPEUTICS CORPORATION | 2005-11-10 | — | — | US | claimed |
| US-20050197336-A1 | Inhibitors of histone deacetylase | MIIKANA THERAPEUTICS CORPORATION | 2005-09-08 | — | — | US | claimed |
| EP-1755601-A2 | INHIBITORS OF HISTONE DEACETYLASE | Miikana Therapeutics, Inc. (US) | 2007-02-28 | — | — | EP | disclosed |
| US-20050250784-A1 | Inhibitors of histone deacetylase | MIIKANA THERAPEUTICS CORPORATION | 2005-11-10 | — | — | US | disclosed |
| WO-2005086898-A2 | INHIBITORS OF HISTONE DEACETYLASE | MIIKANA THERAPEUTICS, INC. (US) | 2005-09-22 | — | — | WO | disclosed |
| US-20050197336-A1 | Inhibitors of histone deacetylase | MIIKANA THERAPEUTICS CORPORATION | 2005-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197336-A1 | Inhibitors of histone deacetylase | HDAC1, HDAC11, HDAC10 | HTR7 2338/4885HTR1A 3714/4885VCP 2325/4885 |
| US-20050250784-A1 | Inhibitors of histone deacetylase | HDAC1, HDAC11, HDAC10 | HTR7 2338/4885HTR1A 3714/4885VCP 2325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.